GV Launches Innovative Stem Cell-Based Products to Expand Presence in Asia

Published: 12 Nov 2025

Author: Precedence Research

Share :

Visionary Holdings Inc. ("GV" or the "Company") has officially launched its medical-grade stem cell anti-ageing product line through its subsidiary, Visionary Health Technology Group Limited. The new product line, designed to deliver advanced regenerative benefits, will initially focus on the Chinese mainland and broader Asian markets, marking a strategic expansion into the region’s premium anti-aging and regenerative medicine sector. This is a big step for the company as it enters the stem cell and medical aesthetics sectors. GV partnered with Jiangsu Yike Regenerative Medicine Co., Ltd. (Yike), and is now moving from just researching to actually selling products, bringing these new regenerative treatments to rich customers.

The product line includes stem cell therapies, NK cell revitalisation, and AI-based diagnostic tools, offering tailored anti-ageing solutions. GV has developed three main programs focusing on high-end clients. There's the total package, which uses stem cells, NK cell therapy, and AI diagnostics, designed for businesspeople and very wealthy individuals who want to fix their cells. These programs target entrepreneurs and ultra-high-net-worth individuals seeking full cellular rejuvenation. GV uses Yike's technology to offer these cell rejuvenation options with stem cells, AI health checks, and tiny delivery systems. They are setting new standards for anti-ageing.

Since Asia is expected to grow rapidly in regenerative aesthetics, GV aims to capture a large share of the market by working closely with medical centres. GV is also trying to improve its stem cell treatment and AI health stuff, hoping to become a leader in cell rejuvenation. GV's goal is to grow and become profitable by matching tech with what people want, and to become better known in the investment world. The company's emphasis on premium offerings, regional growth, and collaboration with leading medical institutions gives it a competitive edge in a specialized field.

Executive’s Statement

Xiyong Hou, CEO of Visionary Holdings

“The official launch of GV’s stem cell-based anti-aging products marks an important milestone in transforming our technological assets into tangible commercial value. Since entering into our strategic partnership and global licensing agreement with Yike, GV has successfully advanced from technology development to market-ready products. As Asia continues to be the fastest-growing market for regenerative aesthetics, this launch not only opens new revenue streams for GV but also establishes a solid foundation for our leadership in longevity and cellular rejuvenation technologies. The company expects this product line to serve as a new driver of profitability in upcoming fiscal years and to strengthen further GV’s visibility and positioning in the global capital markets.”